ACC Expert Consensus Decision Pathway for Bleeding Management: Applications in Patients on Oral Anticoagulants and Cost Implications

TARGET AUDIENCE
Cardiologists, internal medicine physicians, primary care physicians, clinical pharmacists, nurse practitioners, physician assistants, nurses, and other clinicians who care for patients with heart failure.

STATEMENT OF NEED/PROGRAM OVERVIEW
Anticoagulant therapy is an essential part of managing many cardiovascular diseases. The last decade has seen an expansion of therapies aimed at managing patients with multiple underlying CV manifestations, including the advent of direct oral anticoagulants (DOACs), which changed the standard of care.

Ultimately, the choice of anticoagulant therapy must be considered in the context of underlying CV disease, as well as complex comorbidities (i.e., renal disease, obesity). As the rapid evolution of evidence‐based practice parallels more widespread use of novel oral anticoagulants, it is imperative that clinicians remain up to date on optimal anticoagulation strategies in CV.

Join an esteemed panel of expert clinicians to review the evidence-based recommendations for use of DOACs in patients with cardiovascular disease, including the management of a major and minor bleeding events. The expert panelists will also evaluate the pharmacoeconomics of current DOAC reversal strategies and the long-term implications for patient morbidity and mortality.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
• Summarize data around emerging indications for DOACs
• Adopt the 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Direct Oral Anticoagulants
• Evaluate long-term impacts on patient morbidity and mortality and cost effectiveness with specific DOAC reversal agents vs usual care with 4F-PCC or aPCC in the critical-care setting